EA018717B1 - Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение - Google Patents

Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение Download PDF

Info

Publication number
EA018717B1
EA018717B1 EA201070636A EA201070636A EA018717B1 EA 018717 B1 EA018717 B1 EA 018717B1 EA 201070636 A EA201070636 A EA 201070636A EA 201070636 A EA201070636 A EA 201070636A EA 018717 B1 EA018717 B1 EA 018717B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
antibodies
sts
область
zeg
Prior art date
Application number
EA201070636A
Other languages
English (en)
Russian (ru)
Other versions
EA201070636A1 (ru
Inventor
Даниэль Перейра
Дженнифер О'Тул
Original Assignee
Имклоун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40364492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA018717(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Имклоун Элэлси filed Critical Имклоун Элэлси
Publication of EA201070636A1 publication Critical patent/EA201070636A1/ru
Publication of EA018717B1 publication Critical patent/EA018717B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
EA201070636A 2007-11-21 2008-11-21 Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение EA018717B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98955807P 2007-11-21 2007-11-21
PCT/US2008/013130 WO2009070294A2 (en) 2007-11-21 2008-11-21 Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof

Publications (2)

Publication Number Publication Date
EA201070636A1 EA201070636A1 (ru) 2010-10-29
EA018717B1 true EA018717B1 (ru) 2013-10-30

Family

ID=40364492

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070636A EA018717B1 (ru) 2007-11-21 2008-11-21 Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение

Country Status (20)

Country Link
US (2) US7947811B2 (es)
EP (1) EP2222703A2 (es)
JP (1) JP5324593B2 (es)
KR (1) KR101227338B1 (es)
CN (1) CN101868478B (es)
AR (1) AR069393A1 (es)
AU (1) AU2008330089B2 (es)
BR (1) BRPI0820218A2 (es)
CA (1) CA2706583A1 (es)
CL (1) CL2008003449A1 (es)
EA (1) EA018717B1 (es)
IL (1) IL204743A (es)
MX (1) MX2010005651A (es)
NZ (1) NZ584271A (es)
PA (1) PA8804901A1 (es)
PE (1) PE20091713A1 (es)
TW (1) TWI417106B (es)
UA (1) UA99633C2 (es)
UY (1) UY31478A1 (es)
WO (1) WO2009070294A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
JP2011509687A (ja) * 2008-01-22 2011-03-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｒｏｎ抗体およびその使用
WO2009099982A1 (en) 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
SI2519543T1 (sl) * 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
US8603478B2 (en) 2010-07-06 2013-12-10 Aveo Pharmaceuticals, Inc. Anti-RON antibodies
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
CA2855818A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. A method of treating lung cancer having an fgfr1 gene amplification or fgfr1 overexpression
RU2015125642A (ru) * 2012-11-30 2017-01-11 Дженентек, Инк. Композиции ron и способы их применения
RU2015140921A (ru) * 2013-02-26 2017-04-03 Роше Гликарт Аг Антитела к mcsp
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
KR20160014563A (ko) * 2014-07-29 2016-02-11 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
WO2016036172A1 (ko) * 2014-09-03 2016-03-10 씨제이헬스케어 주식회사 단백질 키나제 억제제에 대한 감수성 예측용 바이오 마커 및 이의 용도
JP2020500834A (ja) * 2016-08-26 2020-01-16 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ マクロファージ刺激タンパク質受容体（又はＲＯＮ（Ｒｅｃｅｐｔｅｕｒ ｄ′Ｏｒｉｇｉｎｅ Ｎａｎｔａｉｓ））抗体及びその使用
WO2018052789A1 (en) 2016-09-08 2018-03-22 Pcm Targetech, Llc Monoclonal antibodies specific to the plexin-semaphorin-integrin (psi) domain of ron for drug delivery and its application in cancer therapy
US20220372125A1 (en) * 2019-10-02 2022-11-24 Aslan Pharmaceuticals Pte. Ltd. Antigen Specific Binding Domains and Antibody Molecules
EP4214229A1 (en) * 2020-09-15 2023-07-26 Duke University Coronavirus antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120557A2 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) * 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE221915T1 (de) 1991-02-22 2002-08-15 American Cyanamid Co Identifizierung eines menschlichen rezeptor- tyrosinkinasegens
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US20020103345A1 (en) * 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
JP2004527456A (ja) 2000-08-09 2004-09-09 イムクローン システムズ インコーポレイティド Ｅｇｆ受容体拮抗剤による過増殖性の疾患の治療
SE518548C2 (sv) 2001-04-11 2002-10-22 Sca Hygiene Prod Ab Absorberande alster med förbättrad diskretion
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
WO2002102854A2 (en) 2001-06-20 2002-12-27 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
US20040101920A1 (en) * 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US20040185506A1 (en) * 2003-03-21 2004-09-23 Heavner George A. Epitope mapping using nuclear magnetic resonance
EP1622942B1 (en) 2003-05-01 2014-11-19 ImClone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120557A2 (en) * 2004-05-13 2005-12-22 Imclone Systems Incorporated Inhibition of macrophage-stimulating protein receptor (ron)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
O'TOOLE JENNIFER M. ET AL.: "Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member". CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, vol. 66, no. 18, 15 September 2006 (2006-09-15), pages 9162-9170, XP009102372, ISSN: 0008-5472, the whole document, pages 9164-8; figures 5a, b, с *
RAMSAY CAMP E. ET AL.: "RON, a Tyrosine Kinase Receptor Involved in Tumor Progression and Metastasis". ANNALS OF SURGICAL ONCOLOGY, SPRINGER-VERLAG, NE, vol. 12, no. 4, 1 April 2005 (2005-04-01), pages 273-281, XP019369668, ISSN: 1534-4681, the whole document *

Also Published As

Publication number Publication date
CN101868478A (zh) 2010-10-20
US7947811B2 (en) 2011-05-24
AU2008330089B2 (en) 2013-09-05
JP2011504176A (ja) 2011-02-03
US20110135631A1 (en) 2011-06-09
BRPI0820218A2 (pt) 2015-06-23
MX2010005651A (es) 2010-06-11
KR101227338B1 (ko) 2013-01-28
CN101868478B (zh) 2013-11-13
IL204743A (en) 2013-10-31
AU2008330089A1 (en) 2009-06-04
PA8804901A1 (es) 2009-06-23
PE20091713A1 (es) 2009-11-13
NZ584271A (en) 2012-05-25
EA201070636A1 (ru) 2010-10-29
UY31478A1 (es) 2009-07-17
US8133489B2 (en) 2012-03-13
UA99633C2 (ru) 2012-09-10
KR20100074293A (ko) 2010-07-01
WO2009070294A2 (en) 2009-06-04
TWI417106B (zh) 2013-12-01
CL2008003449A1 (es) 2010-02-19
CA2706583A1 (en) 2009-06-04
AR069393A1 (es) 2010-01-20
IL204743A0 (en) 2010-11-30
JP5324593B2 (ja) 2013-10-23
TW200936161A (en) 2009-09-01
US20090136510A1 (en) 2009-05-28
EP2222703A2 (en) 2010-09-01
WO2009070294A3 (en) 2009-08-20

Similar Documents

Publication Publication Date Title
EA018717B1 (ru) Антитело или фрагмент антитела, которое связывается с белком ron человека, и его применение
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
US20210220472A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
US20210403553A1 (en) Combination therapy for treatment of disease
KR102490997B1 (ko) 암의 치료에 클라우딘 18.2에 대한 항체를 이용하는 치료법
KR101261749B1 (ko) 항-ＥｒｂＢ2 항체 투여 치료 방법
EA019595B1 (ru) СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
KR20020000223A (ko) 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법
JPH03502885A (ja) 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
JP6967003B2 (ja) がんの処置のための方法および組成物
AU2009255305B2 (en) Monoclonal antibodies to basic fibroblast growth factor
TW201834696A (zh) 藉由投予抗her3抗體－藥物複合體之egfr－tki抗性之非小細胞肺癌的治療方法
CN110636861B (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
JP2019512262A (ja) エンドシアリン結合抗体
US20220072144A1 (en) Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
JP2021524251A (ja) Ｃｄ３に特異的な抗体及びその使用
KR20210031679A (ko) 수모-활성화 효소 저해제 및 항-cd20 항체의 투여
CN111848805A (zh) 用于肿瘤免疫治疗的具有双Her2位点的双特异性抗体
US20230233540A1 (en) Combination of antibody-drug conjugate and cdk9 inhibitor
KR20240055868A (ko) 항체-약물 접합체의 용도, 조합 약물 및 이의 용도
ES2739925T3 (es) Agente específico de RANKL para el tratamiento de una enfermedad metastásica
EP3082858B1 (en) Adrenomedullin binder for use in therapy of cancer
CN115814104A (zh) 抗体药物偶联物制剂及其用途
WO2022075482A1 (ja) がん治療用医薬
CN115884794A (zh) 抗her2抗体药物缀合物与her二聚化抑制剂的组合

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ RU